Although inhibition of given cytokine was observed, IL-17A with secukinumab [99], ustekinumab (human monoclonal antibody targeting the IL-12/23 p40 subunit) and guselkumab (monoclonal antibody targeting IL-23 specifically), the treatment did not significantly reduce the signs and symptoms of RA [100]. The gene discussed is IL17A; the disease is rheumatoid arthritis.